VanEck Biotech ETF
BBH
120 hedge funds and large institutions have $155M invested in VanEck Biotech ETF in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 7 closing their positions.
284% more capital inflows, than outflows
Capital inflows: $24.5M | Capital outflows: $6.38M
229% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 7
18% more funds holding
Funds holding: 102 → 120 (+18)
15% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 26
3% more ownership
Funds ownership: 28.36% → 31.37% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Conservest Capital Advisors
Wynnewood,
Pennsylvania
|
+$3.23M |
| 2 |
LPL Financial
San Diego,
California
|
+$2.65M |
| 3 |
L.J. Altfest & Co
New York
|
+$2.47M |
| 4 |
Goldman Sachs
New York
|
+$2.04M |
| 5 |
Tocqueville Asset Management
New York
|
+$1.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.67M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$831K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$657K |
| 4 |
Traphagen Investment Advisors
Oradell,
New Jersey
|
-$588K |
| 5 |
World Equity Group
Schaumburg,
Illinois
|
-$282K |
BBH Hedge Fund Activity: Q4 2022 in Review
120 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2022, worth a combined $155M — up 28% from $121M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BBH positions and 7 closed out — a net gain of 16 holders — while 30 added to existing stakes and 26 trimmed.
The largest buyer was Conservest Capital Advisors, opening a new position worth an estimated $3.23M. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.67M sold.
- 120 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2022, up from 102 in Q3 2022.
- Funds reported $155M of VanEck Biotech ETF stock for Q4 2022, up 28% quarter-over-quarter.
- 23 funds opened new VanEck Biotech ETF positions in Q4 2022 and 7 closed out, a net change of +16 holders.
- The largest VanEck Biotech ETF buyer in Q4 2022 was Conservest Capital Advisors, an estimated $3.23M added.
- The largest VanEck Biotech ETF seller in Q4 2022 was Citadel Advisors, an estimated $1.67M sold.
Based on aggregated 13F filings for Q4 2022.